Fulgent Genetics (NASDAQ:FLGT) Issues FY25 Earnings Guidance

Fulgent Genetics (NASDAQ:FLGT) issued an update on its FY25 earnings guidance on Friday morning. The company provided EPS guidance of $(0.65) for the period, compared to the consensus EPS estimate of ($0.15). The company issued revenue guidance of $310.0 million, compared to the consensus revenue estimate of $324.65 million. Fulgent Genetics also updated its FY 2025 guidance to -0.650–0.650 EPS.

Fulgent Genetics Price Performance

FLGT stock opened at $15.45 on Friday. The firm’s fifty day simple moving average is $17.32 and its 200-day simple moving average is $19.46. The company has a market capitalization of $472.57 million, a P/E ratio of -2.80 and a beta of 1.39. Fulgent Genetics has a 12 month low of $15.21 and a 12 month high of $25.11.

Analyst Ratings Changes

A number of brokerages recently issued reports on FLGT. StockNews.com downgraded shares of Fulgent Genetics from a “hold” rating to a “sell” rating in a report on Wednesday, November 27th. Piper Sandler lowered their price target on shares of Fulgent Genetics from $26.00 to $22.00 and set a “neutral” rating on the stock in a report on Monday, November 11th.

About Fulgent Genetics

Fulgent Genetics, Inc, together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company’s clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases.